Array synthesis of novel lipodepsipeptide

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 23, 2003, Pages 4245-4249

  Siedlecki, James ^a   Hill, Jason ^a   Parr, Ian ^a   Yu, Xiang ^a   Morytko, Michael ^a   Zhang, Yanzhi ^a   Silverman, Jared ^a   Controneo, Nicole ^a   Laganas, Valerie ^a   Li, Tongchuan ^a   Li, Jianshi ^a   Keith, Dennis ^a   Shimer, George ^a   Finn, John ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DAPTOMYCIN; LIPODEPSIPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; LETHALITY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 10744225279     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.07.025     Document Type: Article

References (21)

1. Nagai K., Kamigiri K., Arao N., Suzumura K.I., Kawano Y., Yamaoka M., Zhang H., Watanabe M., Suzuki K. J. Antibiot. 56:2003;123.
2. Wakefield, B. D.; Thorarensen, A.; Zurenko, G. E.; Sweeney, M. T. 225th National Meeting of the American Chemical Society, New Orleans, LA, March 23-27, 2003.
3. Asaka, T.; Manaka, A.; Tanikawa, T.; Sugimoto, T.; Shimazaki, Y.; Sato, M. PCT Int. Appl., 2003, WO 2002-JP8081. CAN 138:170458.
4. McCoy A.J., Sandlin R.C., Maurelli A.T. J. Bacteriol. 185:2003;1218.
5. Green D.W. Exp. Opin. Invest. Drugs. 6:2002;1.
6. Coates A., Hu Y., Bax R., Page C. Nature Rev. Drug Disc. 1:2002;895.
7. Chopra I., Hesse L., O'Neill A. Pharmacochem. Lib. 32:2002;213.
8. Debono F., Barnhart M., Carrell C.B., Hoffmann J.A., Occolowitz J.L., Abbott B.J., Fukuda D.S., Hamill R.L. J. Antibiot. 40:1987;761.
9. Chang S., Sievert D.M., Hageman J.C., Boulton M.L., Tenover F.C., Downes F.P., Shah S., Rudrik J.T., Pupp F.R., Bown W.J., Cardo D., Fridkin S.D. N. Engl. J. Med. 348:2003;1342.
10. Tally F.P., Zeckel M., Wasilewski M.M., Carini C., Berman C.L., Drusano G.L., Oleson F.P. Jr. Exp. Opin. Invest. Drugs. 8:1999;1223.
11. Thorne G.M., Alder J. Clin. Micro. News. 24:2002;33.
12. Rybak M.J., Hershberger E., Moldovan T., Grucz R.G. Antimicrob. Agents Chemother. 44:2000;1062.
13. Atkins R.L., Rybak M. J. Antimicrob. Agents Chemother. 45:2001;454.
14. Lakey J.H., Ptak M. Biochemistry. 27:1998;4639.
15. Silverman J.A., Perlmutter N.G., Shapiro H.M. Antimicrob. Agents Chemother. 47:2003;2538.
16. 18 Heat-inactivated pooled human serum was included at 10% where indicated.
17. Wayne, P. A. NCCLS 2003 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 6th ed.; Document M7-A6, NCCLS Wayne, PA, USA.
18. Silverman J.A., Oliver N., Andrew T., Li T.C. Antimicrob. Agents. Chemother. 45:2001;1799.
19. 20,21 The MIC of the resulting compound was found to be 25 ug/mL against MSSA. The deacylated daptomycin without the ornithine modification is inactive.
20. Debono M., Abbott B.J., Molloy M., Fukuda D.S., Hunt A.H., Daupert V.M., Counter F.T., Ott J.L., Carrell C.B., Howard L.C., Boeck L.-V.D., Hamill R.L. J. Antibiot. 41:1988;1093.
21. Boeck L.-V.D., Fukuda D.S., Abbott B.J., Debono M. J. Antibiot. 41:1998;1085.